生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
ZOLL
Receives Innovative Technology Contract from
Vizient
for TherOx SuperSaturated Oxygen (SSO2) Therapy
2024-04-02
·
BioSpace
Contract awarded for products that bring improvement to cardiovascular care CHELMSFORD, Mass.--(BUSINESS WIRE)-- Zoll, LLC®, an
Asahi Kasei
company that manufactures medical devices and related software solutions, announced today that it has received an Innovative Technology contract from Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company. The contract was awarded based on the recommendation of hospital experts who serve on one of
Vizient
’s customer-led councils, and it signifies unique qualities that potentially bring improvement to patient cardiovascular care. Innovative Technology contracts are recommended after review and interaction with products submitted through
Vizient
’s Innovative Technology Program.
Vizient
customer-led councils identify technologies that have the potential to enhance clinical care, patient safety, healthcare worker safety, or improve business operations of healthcare organizations. “Each year, more than 258,000 patients in the U.S. access emergency rooms as a result of
heart attacks,1
” said Matt Rochner,
TherOx
General Manager. “SSO2 therapy can benefit patients facing the most lethal of
heart attacks
, the LAD-STEMI.2
ZOLL
is very pleased to work with
Vizient
to offer this new, innovative technology to
Vizient
customer hospitals.” Patients with left anterior
descending ST-elevation myocardial infarction (LAD STEMI)
heart attacks
have higher mortality rates than other types of
heart attacks
. SSO2 Therapy is the first and only FDA-approved treatment that has been clinically proven to significantly reduce damage to cardiac muscle in
heart attack
patients after coronary angioplasty with stenting.3 The extent of damaged cardiac muscle is a strong predictor of future outcomes like rehospitalization and the development of
heart failure.4
SSO2 Therapy is indicated for patients who suffer a
LAD STEMI
— also known as "
widowmaker" heart attacks
due to the high mortality rate — and are treated with stenting within six hours of symptom onset. The therapy delivers high levels of dissolved oxygen at 7–10 times the normal amount directly to the damaged heart muscle immediately after the coronary artery has been successfully opened via angioplasty and stenting. Multiple clinical trials have demonstrated the safety and efficacy of SSO2 Therapy to reduce
infarct
size.3, 5 - 8 “A product receives this type of contract when it demonstrates a unique quality that differentiates it from other products on the market,” said Kelly Flaharty, senior director of contract services for
Vizient
. “Our customer-led council determined that
TherOx
SuperSaturated Oxygen (SSO2) Therapy met this standard and recognizes its potential to improve quality outcomes.”
Vizient
represents a diverse customer base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute healthcare providers and has a portfolio that represents more than $130 billion in annual purchasing volume. Through its Innovative Technology Program,
Vizient
works with customer-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare.
Vizient
may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle. About
ZOLL
ZOLL
, an
Asahi Kasei
company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and
sleep apnea
diagnosis and treatment,
ZOLL
provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit . About
Asahi Kasei
The
Asahi Kasei Group
contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses,
Asahi Kasei
has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit .
Asahi Kasei
is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit . 1 Ahuja KR, Saad AM, Nazir S, Ariss RW, Shekhar S, Isogai T, Kassis N, Mahmood A, Sheikh M, Kapadia SR. Trends in Clinical Characteristics and Outcomes in
ST-Elevation Myocardial Infarction
Hospitalizations in the United States, 2002-2016. Curr Probl Cardiol. 2022 Dec;47(12):101005. doi: 10.1016/j.cpcardiol.2021.101005. Epub 2021 Oct 7. PMID: 34627825. 2 What is a
STEMI Heart Attack
? (clevelandclinic.org) 3 Stone GW, et al. Circ Cardiovasc Intervent 2009;2:366-75. 4 Stone GW et al. J Am Coll Cardiol. 2016;67(14):1674–83. 5 O’Neill WW, et al. Jour of Am Coll Cardiol. 2007;50: 5:397-405. 6 David SW, et al. Catheter Cardiovasc Interv. 2018;1–9. 7 8 Chen S, et al. Catheter Cardiovasc Interv. 2020; 1–7. Copyright © 2024
ZOLL Medical Corporation
. All rights reserved.
ZOLL
and
TherOx
are registered trademarks of
ZOLL Medical Corporation
and/or its subsidiaries in the United States and/or other countries.
Asahi Kasei
is a registered trademark of
Asahi Kasei Corporation
. All other trademarks are the property of their respective owners.
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Zoll Foundation
Vizient LLC
Asahi Kasei Corp.
[+2]
适应症
心肌梗塞
心脏衰竭
ST段抬高心肌梗死
[+2]
靶点
-
药物
-
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务